BioStock: Xbrane's CEO on the launch of Ximluci in Europe

Together with its partner STADA, the biosimilar company Xbrane Biopharma is currently in the process of launching Ximluci, a biosimilar to the reference drug Lucentis for the treatment of a serious eye disease. In connection with the BioStock Investor Meeting, the company's CEO Martin Åmark talked about the product launch, the plans for the upcoming US launch and the licensing plans for the oncology portfolio.

Watch the interview with Martin Åmark at biostock.se:

https://www.biostock.se/en/2023/03/xbranes-ceo-on-the-launch-of-ximluci-in-europe/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/